These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23437776)

  • 1. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.
    Abdul-Hay SO; Lane AL; Caulfield TR; Claussin C; Bertrand J; Masson A; Choudhry S; Fauq AH; Maharvi GM; Leissring MA
    J Med Chem; 2013 Mar; 56(6):2246-55. PubMed ID: 23437776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.
    Leissring MA; Malito E; Hedouin S; Reinstatler L; Sahara T; Abdul-Hay SO; Choudhry S; Maharvi GM; Fauq AH; Huzarska M; May PS; Choi S; Logan TP; Turk BE; Cantley LC; Manolopoulou M; Tang WJ; Stein RL; Cuny GD; Selkoe DJ
    PLoS One; 2010 May; 5(5):e10504. PubMed ID: 20498699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.
    Malito E; Ralat LA; Manolopoulou M; Tsay JL; Wadlington NL; Tang WJ
    Biochemistry; 2008 Dec; 47(48):12822-34. PubMed ID: 18986166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.
    Adamek RN; Suire CN; Stokes RW; Brizuela MK; Cohen SM; Leissring MA
    ChemMedChem; 2021 Jun; 16(11):1775-1787. PubMed ID: 33686743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.
    Song ES; Juliano MA; Juliano L; Hersh LB
    J Biol Chem; 2003 Dec; 278(50):49789-94. PubMed ID: 14527953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
    Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
    Çakir B; Dağliyan O; Dağyildiz E; Bariş İ; Kavakli IH; Kizilel S; Türkay M
    PLoS One; 2012; 7(2):e31787. PubMed ID: 22355395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice.
    Deprez-Poulain R; Hennuyer N; Bosc D; Liang WG; Enée E; Marechal X; Charton J; Totobenazara J; Berte G; Jahklal J; Verdelet T; Dumont J; Dassonneville S; Woitrain E; Gauriot M; Paquet C; Duplan I; Hermant P; Cantrelle FX; Sevin E; Culot M; Landry V; Herledan A; Piveteau C; Lippens G; Leroux F; Tang WJ; van Endert P; Staels B; Deprez B
    Nat Commun; 2015 Sep; 6():8250. PubMed ID: 26394692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.
    Abdul-Hay SO; Bannister TD; Wang H; Cameron MD; Caulfield TR; Masson A; Bertrand J; Howard EA; McGuire MP; Crisafulli U; Rosenberry TR; Topper CL; Thompson CR; Schürer SC; Madoux F; Hodder P; Leissring MA
    ACS Chem Biol; 2015 Dec; 10(12):2716-24. PubMed ID: 26398879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
    Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
    Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4321-6. PubMed ID: 14643318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
    Pivovarova O; Höhn A; Grune T; Pfeiffer AF; Rudovich N
    Ann Med; 2016 Dec; 48(8):614-624. PubMed ID: 27320287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme.
    Zhang Z; Liang WG; Bailey LJ; Tan YZ; Wei H; Wang A; Farcasanu M; Woods VA; McCord LA; Lee D; Shang W; Deprez-Poulain R; Deprez B; Liu DR; Koide A; Koide S; Kossiakoff AA; Li S; Carragher B; Potter CS; Tang WJ
    Elife; 2018 Mar; 7():. PubMed ID: 29596046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
    Guo Q; Manolopoulou M; Bian Y; Schilling AB; Tang WJ
    J Mol Biol; 2010 Jan; 395(2):430-43. PubMed ID: 19896952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.
    Charton J; Gauriot M; Totobenazara J; Hennuyer N; Dumont J; Bosc D; Marechal X; Elbakali J; Herledan A; Wen X; Ronco C; Gras-Masse H; Heninot A; Pottiez V; Landry V; Staels B; Liang WG; Leroux F; Tang WJ; Deprez B; Deprez-Poulain R
    Eur J Med Chem; 2015 Jan; 90():547-67. PubMed ID: 25489670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
    Fernández-Gamba A; Leal MC; Morelli L; Castaño EM
    Curr Pharm Des; 2009; 15(31):3644-55. PubMed ID: 19925417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme.
    McCord LA; Liang WG; Dowdell E; Kalas V; Hoey RJ; Koide A; Koide S; Tang WJ
    Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13827-32. PubMed ID: 23922390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.
    Durham TB; Toth JL; Klimkowski VJ; Cao JX; Siesky AM; Alexander-Chacko J; Wu GY; Dixon JT; McGee JE; Wang Y; Guo SY; Cavitt RN; Schindler J; Thibodeaux SJ; Calvert NA; Coghlan MJ; Sindelar DK; Christe M; Kiselyov VV; Michael MD; Sloop KW
    J Biol Chem; 2015 Aug; 290(33):20044-59. PubMed ID: 26085101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
    Leroux F; Bosc D; Beghyn T; Hermant P; Warenghem S; Landry V; Pottiez V; Guillaume V; Charton J; Herledan A; Urata S; Liang W; Sheng L; Tang WJ; Deprez B; Deprez-Poulain R
    Eur J Med Chem; 2019 Oct; 179():557-566. PubMed ID: 31276900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
    Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
    J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.